Ignite Creation Date:
2025-12-24 @ 2:35 PM
Ignite Modification Date:
2026-01-16 @ 6:49 AM
Study NCT ID:
NCT01990859
Status:
COMPLETED
Last Update Posted:
2016-03-14
First Post:
2013-11-18
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Phase 2 Study of Ipilimumab in Japanese Advanced Melanoma Patients
Sponsor:
Bristol-Myers Squibb
Organization:
Study Overview
Official Title:
Phase 2 Study of Ipilimumab in Japanese Subjects With Unresectable or Metastatic Melanoma
Status:
COMPLETED
Status Verified Date:
2016-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to assess the safety of Ipilimumab monotherapy in Japanese subjects with advanced melanoma
Detailed Description:
None
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: